RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Ezetimibe Plus Simvastatin More Beneficial Than Simvastatin Alone in Reducing Recurrent Cardiovascular Events
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 5
SP 18
OP 19
DO 10.1177/1559897715583842
UL http://mdc.sagepub.com/content/15/5/18.abstract
AB Results from IMPROVE-IT showed that adding ezetimibe to statin therapy with simvastatin significantly reduced the primary end point in moderate- to high-risk patients stabilized after acute coronary syndromes. A new analysis from IMPROVE-IT showed that the number of first and recurrent primary end point events was also reduced with combination therapy vs monotherapy over the median 6-year follow-up.